MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer

Inclusion Criteria:

• CT features suggestive of HCC, including those features which have been describedherein; they are also enumerated below:

• For an arterially-enhancing lesion greater than or equal to 1 cm, but under 2 cm,all of the following criteria must be met:

• Imaging features of a mass

• Wash-out on later phases of contrast administration

• At least 1 cm or more growth

• For an arterially-enhancing lesion greater than or equal to 2 cm, two of thefollowing criteria must be met:

• Imaging features of a mass

• Wash-out on later phases of contrast administration

• At least 1 cm or more growth

• All enhancing lesions with expansile, solid, enhancing tumor within vascularstructures will be included, including the main portal vein, the main right andmain left portal veins, the inferior vena cava (IVC), and the main hepatic veins

• No prior history of treatment of liver lesions

• Able to provide written and verbal informed consent

• Able to tolerate a complete abdominal MR examination, within 3 weeks of CT

Exclusion Criteria:

• Unable to provide written and verbal informed consent

• Unable to undergo MRI due to intraocular metallic foreign body, pacemaker, or othercontraindications including objects in the body which are deemed to be unsafe ornotable to be assessed, or unable to undergo MRI within 3 weeks of CT

• Pregnancy

• Severe renal insufficiency as defined by an estimated glomerular filtration rate ofless than 30 cc/minute

• Severe liver disease as defined by Childs class C cirrhosis

• History of a previous reaction to contrast media

• History of bronchial asthma

• History of allergic disorders

• Acute renal insufficiency of any severity due to the hepato-renal syndrome or in theperioperative liver transplantation period